Skip to main content

Advertisement

SpringerLink
Log in

Denosumab in Breast Cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Bone destruction is mediated by osteoclasts, whose formation, function, and survival requires the receptor activator of NF-kB ligand (RANKL). Denosumab is a fully human monoclonal antibody to RANKL, thereby inhibiting osteoclast-mediated bone destruction, and blocks the vicious cycle of cancer-mediated bone disease. In breast cancer patients with bone metastases, denosumab was superior to zoledronic acid in delaying time to first on-study skeletal-related event (SRE; HR = 0.82; P = 0.01 superiority) and time to first and subsequent on-study SREs (HR = 0.77; P = 0.001). Overall survival, disease progression, and serious adverse events were similar between groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s–6249s.

    Article  PubMed  Google Scholar 

  2. Lipton A, Cook RJ, Major P, et al.: Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007, 12:1035–1043.

    Article  CAS  PubMed  Google Scholar 

  3. Rodan GA: The development and function of the skeleton and bone metastases. Cancer 2003, 97:726–732.

    Article  PubMed  Google Scholar 

  4. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655–1664.

    Article  CAS  PubMed  Google Scholar 

  5. Lacey DL, Timms E, Tan HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165–176.

    Article  CAS  PubMed  Google Scholar 

  6. Lacey DL, Tan HL, Li J, et al.: Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435–448.

    CAS  PubMed  Google Scholar 

  7. Simonet WS, Lacey DL, Dunstan CR, et al.: Osteoprotegerin is a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309–319.

    Article  CAS  PubMed  Google Scholar 

  8. Fuller K, Wong B, Fox S, et al.: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998, 188:997–1000.

    Article  CAS  PubMed  Google Scholar 

  9. Yasuda H, Shima N, Nakagava N, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin in osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597–3601.

    Article  CAS  PubMed  Google Scholar 

  10. Yasuda J, Shima N, Nakagawa N, et al.: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG:OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329–1337.

    Article  PubMed  Google Scholar 

  11. Yasuda H, Shima N, Nakagawa N, et al.: A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999, 25:109–113.

    Article  CAS  PubMed  Google Scholar 

  12. Blair JM, Zhou H, Seibel MJ, et al.: Mechanisms of disease roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 2006, 3:41–49.

    Article  CAS  PubMed  Google Scholar 

  13. Clines GA, Guise TA: Hypercalcemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endo Relat Cancer 2005, 12:549–583.

    Article  CAS  Google Scholar 

  14. Guise TA, Mohammad KS, Clines G, et al.: Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s–6216s.

    Article  CAS  PubMed  Google Scholar 

  15. Shapiro CL, Manoola J, Lbeoff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001, 19:3306–3311.

    CAS  PubMed  Google Scholar 

  16. • Hadji P, Ziller M, Kieback DG, et al.: Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomized substudy. Ann Oncol 2009, 20:1203–1209. This study highlights the bone loss that accompanies treatment with an aromatase inhibitor.

    Article  CAS  PubMed  Google Scholar 

  17. Mincey GA, Duh MS, Thomas SK, et al.: Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006, 7:127–132.

    Article  CAS  PubMed  Google Scholar 

  18. • Eastell R, Adams JE, Coleman RE, et al.: Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen alone or in combination trial. J Clin Oncol 2008, 26:1051–1057. This article details the importance of bone loss associated with long-term treatment (5 years) with an aromatase inhibitor.

    Article  CAS  PubMed  Google Scholar 

  19. Morony S, Capparelli C, Sarosi I, et al.: Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001, 61:4432–4436.

    CAS  PubMed  Google Scholar 

  20. Lipton A, Steger GG, Figueroa J, et al.: Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007, 25:4431–4435.

    Article  CAS  PubMed  Google Scholar 

  21. • Fizazi K, Lipton A, Mariette X, et al.: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009, 27:1564–1572. This article reports results of a trial comparing denosumab with continued zoledronic acid in patients who have high bone resorption on bisphosphonate therapy.

    Article  CAS  PubMed  Google Scholar 

  22. • Ellis GK, Bone HG, Chlebowski R, et al.: Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26:4875–4882. This article found that denosumab prevents loss of BMD associated with aromatase inhibitor therapy.

    Article  CAS  PubMed  Google Scholar 

  23. Hosking D, Chilvers CE, Christiansen C, et al.: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998, 338:485–492.

    Article  CAS  PubMed  Google Scholar 

  24. • Stopeck AT, Lipton A, Body JJ, et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010, In press. This article reports results from a phase 3 trial comparing denosumab versus zoledronic acid in patients with breast cancer and bone metastases.

Download references

Disclosure

A. Lipton: consultant for Amgen, Novartis; expert testimony for Novartis; honoraria from Amgen, Novartis; laboratory research support from Novartis.

Author information

Authors and Affiliations

  1. Professor of Medicine and Oncology, Division of Hematology and Oncology, MS Hershey Medical Center, 500 University Drive, Hershey, PA, 17033, USA

    Allan Lipton

Authors
  1. Allan Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Allan Lipton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lipton, A. Denosumab in Breast Cancer. Curr Oncol Rep 13, 1–4 (2011). https://doi.org/10.1007/s11912-010-0135-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-010-0135-y

Keywords

Search

Navigation